Применение тофацитиниба при псориатическом артрите (обзор литературы)

Введение. Псориатический артрит (ПсА) – хроническое системное иммуноопосредованное воспалительное заболевание опорно-двигательного аппарата, представляет собой сложную воспалительную артропатию с гетерогенным спектром проявлений. Стойкое воспаление может привести к разрушению суставов и инвалидизации, которые можно предотвратить при ранней диагностике и лечении. Несмотря на обширный терапевтический арсенал, контроль заболевания у значительной части пациентов является неоптимальным. Представляет интерес оценка эффективности ингибитора янус-киназ (JAK-киназ) тофацитиниба при лечении псориаза и ПсА.

Цель. Оценить возможности применения тофацитиниба при лечении псориаза и псориатического артрита.

Материалы и методы. Выполнен поиск литературы по данной тематике в базах электронных научных медицинских библиотек PubMed, PubMed Central, Scopus, eLibrary.Ru (до 29 февраля 2024 г.). Наша обзорная научная статья основана на ранее проведенных исследованиях и не содержит каких-либо исследований с участием животных или людей, проведенных кем-либо из авторов нашей статьи.

Результаты. Рандомизированные контролируемые исследования продемонстрировали высокую эффективность тофацитиниба при лечении ПсА. Тофацитиниб является современным эффективным лекарственным препаратом для лечения псориаза и ПсА с хорошим профилем эффективности и приемлемым профилем безопасности. Дальнейшие долгосрочные расширенные исследования и клинические данные помогут расширить роль тофацитиниба в лечении этих заболеваний.

Заключение. Литературные данные свидетельствуют о высокой эффективности тофацитиниба при лечении псориаза и псориатического артрита. Применение тофацитиниба является многообещающим в лечении пациентов с ПсА, особенно пациентов, отягощенных остаточными явлениями заболевания и болью.

1. Boehncke WH, Schön MP. Psoriasis. Lancet. 2015;386(9997):983–994. https://doi.org/10.1016/S0140-6736(14)61909-7.

2. Napolitano M, Caso F, Scarpa R, Megna M, Patrì A, Balato N, Costa L. Psoriatic arthritis and psoriasis: differential diagnosis. Clin Rheumatol. 2016;35(8):1893–1901. https://doi.org/10.1007/s10067-016-3295-9.

3. Megna M, Potestio L, Ruggiero A, Cacciapuoti S, Maione F, Tasso M et al. JAK Inhibitors in Psoriatic Disease. Clin Cosmet Investig Dermatol. 2023;16:3129–3145. https://doi.org/10.2147/CCID.S433367.

4. Caso F, Del Puente A, Oliviero F, Peluso R, Girolimetto N, Bottiglieri P et al. Metabolic syndrome in psoriatic arthritis: the interplay with cutaneous involvement. Evidences from literature and a recent cross-sectional study. Clin Rheumatol. 2018;37(3):579–586. https://doi.org/10.1007/s10067-017-3975-0.

5. Toussirot E, Gallais-Sérézal I, Aubin F. The cardiometabolic conditions of psoriatic disease. Front Immunol. 2022;13:970371. https://doi.org/10.3389/fimmu.2022.970371.

6. Marasca C, Ruggiero A, Annunziata MC, Fabbrocini G, Megna M. Face the COVID-19 emergency: measures applied in an Italian dermatologic clinic. J Eur Acad Dermatol Venereol. 2020;34(6):e249. https://doi.org/10.1111/jdv.16476.

7. Ruggiero A, Megna M, Fabbrocini G, Martora F. Video and telephone teledermatology consultations during COVID-19 in comparison: patient satisfaction, doubts and concerns. Clin Exp Dermatol. 2022;47(10):1863–1864. https://doi.org/10.1111/ced.15286.

8. Ogdie A, Gelfand JM. Clinical risk factors for the development of psoriatic arthritis among patients with psoriasis: a review of available evidence. Curr Rheumatol Rep. 2015;17(10):64. https://doi.org/10.1007/s11926-015-0540-1.

9. Mishra S, Kancharla H, Dogra S, Sharma A. Comparison of four validated psoriatic arthritis screening tools in diagnosing psoriatic arthritis in patients with psoriasis (COMPAQ Study). Br J Dermatol. 2017;176(3):765–770. https://doi.org/10.1111/bjd.14929.

10. Tucker LJ, Coates LC, Helliwell PS. Assessing Disease Activity in Psoriatic Arthritis: a Literature Review. Rheumatol Ther. 2019;6(1):23–32. https://doi.org/10.1007/s40744-018-0132-4.

11. Gossec L, de Wit M, Kiltz U, Braun J, Kalyoncu U, Scrivo R et al. A patientderived and patient-reported outcome measure for assessing psoriatic arthritis: elaboration and preliminary validation of the psoriatic arthritis impact of disease (PsAID) questionnaire, a 13-country EULAR initiative. Ann Rheum Dis. 2014;73:1012–1019. https://doi.org/10.1136/annrheumdis-2014-205207.

12. Punchard NA, Whelan CJ, Adcock I. The Journal of inflammation. J Inflamm. 2004;1:1. https://doi.org/10.1186/1476-9255-1-1.

13. Dougados M, Taylor PC, Bingham CO 3rd, Fallon L, Brault Y, Roychoudhury S et al. The effect of tofacitinib on residual pain in patients with rheumatoid arthritis and psoriatic arthritis. RMD Open. 2022;8(2):e002478. https://doi.org/10.1136/rmdopen-2022-002478.

14. Kilic G, Kilic E, Nas K, Kamanlı A, Tekeoglu İ. Residual symptoms and disease burden among patients with psoriatic arthritis: is a new disease activity index required? Rheumatol Int. 2019;39:73–81. https://doi.org/10.1007/s00296-018-4201-3.

15. Nieto FR, Clark AK, Grist J, Hathway GJ, Chapman V, Malcangio M. Neuronimmune mechanisms contribute to pain in early stages of arthritis. J Neuroinflammation. 2016;13:96. https://doi.org/10.1186/s12974-016-0556-0.

16. Mease PJ, Young P, Fallon L, Mundayat R, Dina O, Blachley T et al. Effectiveness of Tofacitinib in Patients Initiating Therapy for Psoriatic Arthritis: Results from the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry. Rheumatol Ther. 2024;11(2):313–329. https://doi.org/10.1007/s40744-023-00631-4.

17. Nash P, Coates LC, Kivitz AJ, Mease PJ, Gladman DD, Covarrubias-Cobos JA et al. Safety and efficacy of tofacitinib in patients with active psoriatic arthritis: interim analysis of OPAL balance, an open-label, long-term extension study. Rheumatol Ther. 2020;7(3):553–580. https://doi.org/10.1007/s40744-020-00209-4.

18. Winthrop KL, Cohen SB. Oral surveillance and JAK inhibitor safety: the theory of relativity. Nat Rev Rheumatol. 2022;18(5):301–304. https://doi.org/10.1038/s41584-022-00767-7.

19. Burmester GR, Nash P, Sands BE, Papp K, Stockert L, Jones TV et al. Adverse events of special interest in clinical trials of rheumatoid arthritis, psoriatic arthritis, ulcerative colitis and psoriasis with 37 066 patient-years of tofacitinib exposure. RMD Open. 2021;7(2):e001595. https://doi.org/10.1136/rmdopen-2021-001595.

20. Padda IS, Bhatt R, Parmar M. Tofacitinib. 2023 Jul 3. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2024. Available at: https://www.ncbi.nlm.nih.gov/books/NBK572148.

21. Harden JL, Krueger JG, Bowcock AM. The immunogenetics of Psoriasis: a comprehensive review. J Autoimmun. 2015;64:66–73. https://doi.org/10.1016/j.jaut.2015.07.008.

22. Rendon A, Schäkel K. Psoriasis Pathogenesis and Treatment. Int J Mol Sci. 2019;20(6):1475. https://doi.org/10.3390/ijms20061475.

23. Ruggiero A, Martora F, Picone V, Potestio L, Camela E, Battista T et al. The impact of COVID-19 infection on patients with psoriasis treated with biologics: an Italian experience. Clin Exp Dermatol. 2022;47(12):2280–2282. https://doi.org/10.1111/ced.15336.

24. Bhosle MJ, Kulkarni A, Feldman SR, Balkrishnan R. Quality of life in patients with psoriasis. Health Qual Life Outcomes. 2006;4:35. https://doi.org/10.1186/1477-7525-4-35.

25. Potestio L, Camela E, Cacciapuoti S, Fornaro L, Ruggiero A, Martora F et al. Biologics for the management of erythrodermic psoriasis: an updated review. Clin Cosmet Investig Dermatol. 2023;16:2045–2059. https://doi.org/10.2147/CCID.S407813.

26. Camela E, Potestio L, Fabbrocini G, Pallotta S, Megna M. The holistic approach to psoriasis patients with comorbidities: the role of investigational drugs. Expert Opin Investig Drugs. 2023;32(6):537–552. https://doi.org/10.1080/13543784.2023.2219387.

27. Zeng R, Spolski R, Casas E, Zhu W, Levy DE, Leonard WJ. The molecular basis of IL-21-mediated proliferation. Blood. 2007;109(10):4135–4142. https://doi.org/10.1182/blood-2006-10-054973.

28. Selmi C, Chimenti MS, Novelli L, Parikh BK, Morello F, de Vlam K, Ciccia F. Pain in axial spondyloarthritis: role of the JAK/STAT pathway. Front Immunol. 2024;15:1341981. https://doi.org/10.3389/fimmu.2024.1341981.

29. Singh S, Pradhan D, Puri P, Ramesh V, Aggarwal S, Nayek A, Jain AK. Genomic alterations driving psoriasis pathogenesis. Gene. 2019;683:61–71. https://doi.org/10.1016/j.gene.2018.09.042.

30. Azuaga AB, Ramírez J, Cañete JD. Psoriatic arthritis: pathogenesis and targeted therapies. Int J Mol Sci. 2023;24(5):4901. https://doi.org/10.3390/ijms24054901.

31. Ishizaki M, Muromoto R, Akimoto T, Sekine Y, Kon S, Diwan M et al. Tyk2 is a therapeutic target for psoriasis-like skin inflammation. Int Immunol. 2014;26(5):257–267. https://doi.org/10.1093/intimm/dxt062.

32. Caso F, Costa L, Chimenti MS, Navarini L, Punzi L. Pathogenesis of Psoriatic Arthritis. Crit Rev Immunol. 2019;39(5):361–377. https://doi.org/10.1615/CritRevImmunol.2020033243.

33. Fiocco U, Accordi B, Martini V, Oliviero F, Facco M, Cabrelle A et al. JAK/ STAT/PKCδ molecular pathways in synovial fluid T lymphocytes reflect the in vivo T helper-17 expansion in psoriatic arthritis. Immunol Res. 2014;58(1):61–69. https://doi.org/10.1007/s12026-013-8481-0.

34. Nast A, Smith C, Spuls PI, Avila Valle G, Bata-Csörgö Z, Boonen H et al. EuroGuiDerm Guideline on the systemic treatment of Psoriasis vulgaris – Part 1: treatment and monitoring recommendations. J Eur Acad Dermatol Venereol. 2020;34(11):2461–2498. https://doi.org/10.1111/jdv.16915.

35. Yang F, Lu C, Wang Y, Liu H, Leng X, Zeng X. Efficacy and safety of Janus kinase inhibitors in patients with psoriasis and psoriatic arthritis: a systematic review and meta-analysis. Clin Rheumatol. 2023;42(6):1593–1605. https://doi.org/10.1007/s10067-023-06529-4.

36. Nast A, Smith C, Spuls PI, Avila Valle G, Bata-Csörgö Z, Boonen H et al. EuroGuiDerm Guideline on the systemic treatment of Psoriasis vulgaris – Part 2: specific clinical and comorbid situations. J Eur Acad Dermatol Venereol. 2021;35(2):281–317. https://doi.org/10.1111/jdv.16926.

37. Spinelli FR, Meylan F, O’Shea JJ, Gadina M. JAK inhibitors: Ten years after. Eur J Immunol. 2021;51(7):1615–1627. https://doi.org/10.1002/eji.202048922.

38. Насонов ЕЛ, Лила АМ. Ингибиторы Янус-киназ при иммуновоспалительных ревматических заболеваниях: новые возможности и перспективы. Научно-практическая ревматология. 2019;57(1):8–16. https://doi.org/10.14412/1995-4484-2019-8-16.

39. Caso F, Costa L, Triggianese P, Maione F, Bertolini N, Vastarella M et al. Recent developments for new investigational JAK inhibitors in psoriatic arthritis. Expert Opin Investig Drugs. 2023;32(5):361–371. https://doi.org/10.1080/13543784.2023.2207737.

40. Navarini L, Currado D, Costa L, Tasso M, Chimenti MS, Caso F. Experimental and investigational pharmacotherapy for psoriatic arthritis: drugs of the future. J Exp Pharmacol. 2020;12:487–502. https://doi.org/10.2147/JEP.S265633.

41. Ghoreschi K, Jesson MI, Li X, Lee JL, Ghosh S, Alsup JW et al. Modulation of innate and adaptive immune responses by tofacitinib (CP-690,550). J Immunol. 2011;186(7):4234–4243. https://doi.org/10.4049/jimmunol.1003668.

42. Leung YY, Korotaeva T, Candia L, Pedersen SJ, Molano WB, Ruderman EM et al. Management of peripheral arthritis in patients with psoriatic arthritis: an updated literature review informing the 2021 GRAPPA treatment recommendations. J Rheumatol. 2022;49(12):1. https://doi.org/10.3899/jrheum.220315.C1.

43. Dowty ME, Lin J, Ryder TF, Wang W, Walker GS, Vaz A et al. The pharmacokinetics, metabolism, and clearance mechanisms of tofacitinib, a janus kinase inhibitor, in humans. Drug Metab Dispos. 2014;42(4):759–773. https://doi.org/10.1124/dmd.113.054940.

44. Papp KA, Menter A, Strober B, Langley RG, Buonanno M, Wolk R et al. Efficacy and safety of tofacitinib, an oral Janus kinase inhibitor, in the treatment of psoriasis: a Phase 2b randomized placebo-controlled dose-ranging study. Br J Dermatol. 2012;167(3):668–677. https://doi.org/10.1111/j.1365-2133.2012.11168.x